Endpoints News
CSL says its hemophilia B gene therapy is out of stock
CSL Behring disclosed a “temporary global stockout” of its gene therapy for hemophilia B that it says could delay treatment for some patients.
In a letter to the patient community
CSL Behring disclosed a “temporary global stockout” of its gene therapy for hemophilia B that it says could delay treatment for some patients.
In a letter to the patient community